• Sales order from Serum Institute of India under 5-year Purchase Agreement of A$213,000 received
• AnteoTech's Life Sciences business on track to achieve ~A$0.93 million sales for FY2025, up 130% over FY2024
• Vidcare project delayed due to Indian regulatory requirements, but collaborative relationship continues to grow
• Prototype assay development program for KOMA in South Korea successfully completed

AnteoTech Ltd (ASX:ADO) is pleased to provide an update on its Life Sciences Business Unit. Key points include:1. Sales order from the Serum Institute of India (SII) under a five-year Purchase Agreement of A$213,000 received. This order, along with others, takes SII beyond the minimum annual order quantity of US$370,000 for FY2025, reflecting the increasing use case for AnteoBindTM at SII.2. AnteoTech's Life Sciences business is on track to achieve ~A$0.93 million in sales for FY2025, a year-on-year increase of approximately 130%.3. While the Vidcare project has been delayed due to Indian regulatory requirements, the collaborative relationship between AnteoTech and Vidcare continues to grow.4. The AnteoTech Life Sciences team has successfully completed the development of a prototype lateral flow assay device on behalf of KOMA Biotech for a South Korean local customer. AnteoTech is awaiting final payment and has a proposal with KOMA for a further work package.

AnteoTech's Life Sciences business is on track to achieve ~A$0.93 million in sales for the 2025 financial year, an increase of approximately 130% over the 2024 financial year.